From Wikipedia, the free encyclopedia
Jump to: navigation, search
  • This article is about the drug abbreviated "TRIAC". For the electronic component, see TRIAC. Also see Triac (car).
Systematic (IUPAC) name
[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
Pharmacokinetic data
Protein binding Presumed high
Metabolism Hepatic glucuronidation
Excretion Biliary
CAS number 51-24-1 N
ATC code H03AA04 D11AX08
PubChem CID 5803
IUPHAR ligand 2637
DrugBank DB03604
ChemSpider 5598 YesY
KEGG D07214 YesY
Synonyms 3,3',5-triiodothyroacetic acid
Chemical data
Formula C14H9I3O4 
Mol. mass 621.932 g/mol
 N (what is this?)  (verify)

Tiratricol (also known as TRIAC or triiodothyroacetic acid) is a thyroid hormone analogue.


It is indicated in the management of thyroid hormone resistance syndrome[1] and is used, in combination with levothyroxine, to suppress thyroid-stimulating hormone production in patients with thyroid cancer.

It has been investigated for use in reducing goiter.[2]

It has also shown some effectiveness in reducing the atrophy caused when using corticosteroids.[3]

Tiratricol has also been widely marketed, under various trade names, as a weight loss aid. In 1999 and 2000, the United States Food and Drug Administration and Health Canada both issued warnings to the public regarding the use of dietary supplements containing tiratricol.[4][5]

Legal status[edit]

Tiratricol is not approved for sale in Canada or the United States. It was once an approved drug in Brazil, but its marketing authorization was suspended in 2003, effectively prohibiting its sale.[6]


  1. ^ Carvalho GA, Ramos HE (2004). "[Thyroid hormone resistance syndrome]". Arq Bras Endocrinol Metabol (in Portuguese) 48 (1): 83–92. doi:10.1590/S0004-27302004000100010. PMID 15611821.  Free full text PDF (95.3 KiB)
  2. ^ Brenta G, Schnitman M, Fretes O, et al. (November 2003). "Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid". J. Clin. Endocrinol. Metab. 88 (11): 5287–92. doi:10.1210/jc.2003-030095. PMID 14602763. 
  3. ^ Yazdanparast P, Carlsson B, Oikarinen A, Risteli J, Lavin T, Faergemann J (November 2006). "Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans". Thyroid 16 (11): 1157–62. doi:10.1089/thy.2006.16.1157. PMID 17123343. 
  4. ^ "FDA Warns Against Consuming Dietary Supplements Containing Tiratricol" (Press release). U.S. Food and Drug Administration. November 21, 2000. Retrieved 2007-08-08. 
  5. ^ "Health Canada issues warning on products containing Tiratricol (TRIAC)" (Press release). Health Canada. December 2, 1999. Retrieved 2007-08-08. 
  6. ^ "Anvisa suspende Tiratricol" (in Portuguese). Brazilian Society of Endocrinology and Metabolism. Archived from the original on 2007-10-09. Retrieved 2007-08-08.